首页> 外文期刊>Clinical and Translational Gastroenterology >Gene Expression Changes Accompanying the Duodenal Adenoma-Carcinoma Sequence in Familial Adenomatous Polyposis
【24h】

Gene Expression Changes Accompanying the Duodenal Adenoma-Carcinoma Sequence in Familial Adenomatous Polyposis

机译:家族性腺瘤性息肉病的十二指肠腺癌-癌序列的基因表达变化

获取原文
       

摘要

OBJECTIVES: Duodenal cancer in familial adenomatous polyposis (FAP) arises from adenomas. Differentially expressed genes (DEGs) in the duodenal adenoma-carcinoma pathway have been identified in murine FAP models, but similar data in patients with FAP are limited. Identifying such changes may have significance in understanding duodenal polyposis therapies and identifying cancer biomarkers. We performed a genome-wide transcriptional analysis to describe the duodenal adenoma-carcinoma sequence and determine changes distinguishing patients with FAP with and without duodenal cancer. METHODS: Transcriptional profiling was performed with the Affymetrix Human Transcriptome Array 2.0 on duodenal biopsies from 12 FAP patients with duodenal cancer (FAP cases) and 12 FAP patients without cancer (FAP controls). DEGs were compared between cancer-normal, adenoma-normal, and cancer-adenoma in FAP cases and between adenomas from FAP cases and FAP controls. Significant results at P & 0.05 were filtered using fold change & 2. RESULTS: Two hundred twenty-four DEGs were identified at an absolute fold change & 2. In adenoma-normal, downregulation of DEGs involved in metabolism of brush border proteins ( LCT ), lipids ( APOB/A4 ), reactive oxygen species ( GSTA2 ), and retinol ( RBP2 ) was observed. In the cancer-adenoma comparison, upregulation of DEGs involved in cell invasion/migration ( POSTN, SPP1 ) and downregulation of DEGs involved in Paneth differentiation ( DEFA5/6 ) were observed. In the adenoma-adenoma comparison, downregulation of several DEGs ( CLCA1 , ADH1C , ANXA10 ) in FAP case adenomas was observed. DEGs with therapeutic potential include SPP1 , which is involved in both cyclooxygenase and epidermal growth factor receptor pathways targeted by the sulindac/erlotinib combination for duodenal polyposis. DISCUSSION: We describe DEGs in the human duodenal adenoma-carcinoma sequence in FAP, which may have prognostic and therapeutic significance. Validation studies are needed to confirm these findings.
机译:目的:家族性腺瘤性息肉病(FAP)的十二指肠癌是由腺瘤引起的。在鼠类FAP模型中已经确定了十二指肠腺瘤-癌途径中的差异表达基因(DEG),但FAP患者的相似数据有限。识别此类变化可能对理解十二指肠息肉病疗法和识别癌症生物标志物具有重要意义。我们进行了全基因组转录分析,以描述十二指肠腺瘤-癌序列,并确定区分患有和不患有十二指肠癌的FAP患者的变化。方法:使用Affymetrix Human Transcriptome Array 2.0对12例十二指肠癌FAP患者(FAP病例)和12例无癌FAP患者(FAP对照)的十二指肠活检进行转录谱分析。比较了FAP病例中癌正常,腺瘤正常和癌性腺瘤之间的DEG,以及FAP病例和FAP对照的腺瘤之间的DEG。在P <0时的显着结果。使用倍数变化> 0.05过滤。结果:在绝对倍数变化> 2的条件下鉴定出了224个DEG。 2.在正常的腺瘤中,观察到与刷缘蛋白(LCT),脂质(APOB / A4),活性氧(GSTA2)和视黄醇(RBP2)代谢有关的DEG的下调。在癌症-腺瘤比较中,观察到参与细胞侵袭/迁移的DEGs的上调(POSTN,SPP1)和参与Paneth分化的DEGs的下调(DEFA5 / 6)。在腺瘤-腺瘤比较中,观察到FAP病例腺瘤中几个DEG(CLCA1,ADH1C,ANXA10)的下调。具有治疗潜力的DEG包括SPP1,它与环氧化酶和表皮生长因子受体途径同时被舒林酸/厄洛替尼联合靶向治疗十二指肠息肉。讨论:我们描述了FAP中人十二指肠腺瘤-癌序列中的DEG,可能具有预后和治疗意义。需要进行验证研究以确认这些发现。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号